# BPC-157 Dosage in the Research: Per-Kilogram Figures and Routes Studied > BPC-157 dosage as the literature expresses it: animal per-kilogram figures, the routes studied, the under-30-minute half-life, and why no validated human protocol exists. Animal per-kilogram figures and the routes studied — a record, not a protocol. ## How BPC-157 Doses Are Expressed in the Literature BPC-157 dosage in the published work is almost entirely an animal, per-body-weight figure — not a human instruction. Rodent studies commonly express dose per kilogram, frequently around `10 microg/kg` and `10 ng/kg`, and as low as `10 pg` per rat in some tendon work [1]. Gastric-ulcer cytoprotection was studied at `400 ng/kg` and `800 ng/kg` in rats [4]. These are model figures; they do not convert into a human dose, and this page does not provide one. The little human dosing that exists comes from the three pilots, and it is heterogeneous: the intravenous safety pilot used `10 mg` then `20 mg` by infusion in two adults [10], and the interstitial-cystitis pilot used a single `10 mg` intravesical dose during cystoscopy [14]. None of these establishes a validated human protocol — they are isolated pilot exposures, not a dosing schedule. ## Routes Studied The route list in the BPC-157 literature is wide, which reflects how exploratory the work has been. Intraperitoneal injection is the most common rodent route [1]. Intramuscular and intragastric routes were compared head-to-head in the gastric-ulcer study, with intramuscular outperforming intragastric [4]. Local and intra-lesional delivery appears in the tendon and wound work [1]. Every human route to date is a single pilot context: intravenous infusion in the safety pilot [10], intravesical instillation in the interstitial-cystitis pilot [14], and intra-articular injection in the knee-pain case series [6]. No route has a validated human dosing protocol attached to it. Route matters for more than convenience here, because it is tied to the regulatory record: FDA's stated concerns about BPC-157 included potential immunogenicity for certain routes of administration [17]. The research record and the regulatory record both treat route as a variable, not a footnote — which is one more reason the animal route data do not collapse into a single human instruction. ## Half-Life and Why It Shapes the Dose Discussion The reported elimination half-life is under `30 min` for the prototype peptide in a rat and dog PK study using intravenous and intramuscular routes [2]. The same study reported linear pharmacokinetics, intramuscular bioavailability of roughly `14-19%` in rats and `45-51%` in dogs, and excretion via urine and bile [2]. A half-life that short means blood levels fall quickly after each dose, which is why rodent protocols typically use repeated daily administration rather than a single exposure [1]. It also means the molecule is cleared and metabolized into small fragments well before the days-long healing outcomes appear. There is no validated human pharmacokinetic profile, so any human dosing interval would be unsupported by data. ## Why Animal Per-Kilogram Figures Do Not Become a Human Dose The most common request the BPC-157 literature cannot fill is a human dose, and the reason is structural, not coy. The bulk of the dosing data is per-kilogram in rats and dogs [1][2][4], and per-kilogram figures do not scale linearly to humans — interspecies differences in metabolism, surface area and clearance mean a rodent `microg/kg` figure has no validated human equivalent. The PK study itself reported different intramuscular bioavailability between rats and dogs — roughly `14-19%` versus `45-51%` [2] — which is a direct demonstration that even two animal species handle the molecule differently. The three human exposures that exist were not dose-finding studies. They were a `10 mg` then `20 mg` intravenous safety pilot in two adults [10] and a single `10 mg` intravesical dose in an interstitial-cystitis pilot [14]; the knee-pain case series did not standardize a dose at all [6]. None was designed to establish how much, how often, or for how long — so no human schedule can be drawn from them. ## Stability, Reconstitution, and the Limits of This Page The peptide is described as a stable gastric pentadecapeptide because it is reported to be stable in human gastric juice, which underlies the research interest in oral and peroral administration [4]. Despite that stability, formal human oral pharmacokinetics are not established [11]. Reconstitution — dissolving a lyophilized peptide in a diluent — and storage practices discussed in research handling are laboratory-context, not validated clinical protocols. This page is a readout of how the studies expressed their doses. It is not a recommendation, a schedule, or a protocol for any person. For how those doses connect to the molecule's mechanism, see the [VEGFR2 angiogenesis mechanism](/research); for the regulatory picture around access, see the [BPC-157 legal status](/legal-status) page. --- A bioluminescent field-station readout of the BPC-157 literature — every figure logged to its source, no clinic in the canopy and nothing here for sale.